Upcoming BioAlliance Pharma's Presentations At International Conferences On Infectious Diseases And Oncology
Main Category: Infectious Diseases / Bacteria / VirusesAlso Included In: Cancer / Oncology; Conferences
Article Date: 22 May 2009 - 3:00 PDT
email to a friend 
printer friendly 
opinions
| Patient / Public: |  | |
| Healthcare Prof: | |
BioAlliance Pharma SA (Paris:BIO), a company dedicated to therapies and supportive care for cancer and AIDS patients, announced its scientific communications at upcoming international conferences on infectious diseases and oncology:
Loramyc®, indicated for fungal infections in immune-compromised patients with HIV or cancer
The 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
May 29 to June 2, 2009 - Orlando, Florida, USA.
Abstract: "Prevalence and management of oropharyngeal candidiasis (OPC) by medical and radiation oncologists in cancer patients".
At the American Conference for the Treatment of HIV (ACTHIV) that took place on May 15-17, 2009 in Denver, Colorado, USA, BioAlliance Pharma presented the poster: "Once-Daily Miconazole Mucoadhesive Buccal Tablet is an Effective and Safe Treatment for Oropharyngeal Candidiasis".
Amep™, a biotherapy for Metastatic Melanoma treatment
American Society of Gene Therapy (ASGT) 12th Annual Meeting
May 27-30, 2009 - San Diego, California, USA
Poster: "Complete Melanoma Regressions after Electrotransfer of the p-AMEP™ Plasmid Coding for an Anti-Angiogenic and Anti-Metastatic Peptide", May 28.
Anti-integrases: new antiretroviral drugs for the treatment of resistant HIV-1
XVIII International HIV Drug Resistance Workshop
June 9-13, 2009 - Fort Myers, Florida, USA
Oral communication and poster: "New integrase binding inhibitors acting in synergy with Raltegravir", June 12.
Irinotecan SRN oral formulation for the treatment of advanced colorectal cancer
2nd Pharmaceutical Sciences Fair and Exhibition (PharmSciFair)
June 8-12, 2009, Nice, France
Oral communication: "Sustained Release Nanoparticles (SRN) for oral administration of Irinotecan", June 10.
Source
BioAlliance Pharma
Visit our infectious diseases / bacteria / viruses section for the latest news on this subject.
MLA
16 Feb. 2012. <http://www.medicalnewstoday.com/releases/151104.php>
APA
http://www.medicalnewstoday.com/releases/151104.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
Privacy Policy |
Terms and Conditions
MediLexicon International Ltd
Bexhill-on-Sea, United Kingdom
MediLexicon International Ltd © 2004-2012 All rights reserved.
